Results 191 to 200 of about 43,444 (242)

Lack of Cerebrospinal Fluid α‐Synuclein Seeding in VPS35 D620N‐ and LRRK2 Y1699C‐Linked Parkinson's Disease

Movement Disorders, Volume 41, Issue 6, Page 1605-1608, June 2026.
Letizia Santinelli, Neringa Pratuseviciute, Lara M. Lange, Teresa Kleinz, Norbert Brüggemann, Linn Streubel‐Gallasch, Meret Möller, Alexander Zimprich, Christof Brücke, Jean‐Marc Good, Norman Griebner, Shalini Padmanabhan, Philip Seibler, Peter Bauer, Wim Vandenberghe, Esther Sammler, Cornelis Blauwendraat, Christine Klein, Max Borsche   +18 more
wiley   +1 more source

Neurotransmitter Systems Underlying Freezing of Gait (FOG) in Parkinson's Disease

European Journal of Neuroscience, Volume 63, Issue 12, June 2026.
Freezing of gait (FOG) in Parkinson's disease (PD) arises from dysfunction across multiple neurotransmitter systems within distributed locomotor networks. While dopaminergic deficits contribute to levodopa‐responsive FOG, nondopaminergic systems including cholinergic, noradrenergic, serotonergic, and glutamatergic/GABAergic pathways play key roles in ...
Minsub Cho, Jin Whan Cho, Dallah Yoo, Jinse Park, Do‐Young Kwon, Seong‐Beom Koh, Jeong‐Ho Park, Jinyoung Youn   +7 more
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Atypical Parkinsonian Disorders

Movement Disorders, 2005
In many neurological diseases the topography of the lesion, whatever its nature, determines the clinical signs, whereas the nature of the lesion (vascular, inflammatory, degenerative, etc.) whatever its topography, determines the time course. According to J. P. Martin (1), this general principle cannot be simply applied to diseases of the basal ganglia
Gregor K. Wenning, Werner Poewe
  +4 more sources

Neuroimaging in Parkinsonian Disorders

Neurology India, 2018
Neuroimaging (NI) in Parkinson's disease (PD) includes functional techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT), and morphological imaging using magnetic resonance imaging (MRI) and transcranial sonography to probe different aspects of the neurobiology of PD.
Madhavi, Tripathi, Atin, Kumar, Chandrasekhar, Bal   +2 more
openaire   +2 more sources

Neuromelanin in parkinsonian disorders: an update

International Journal of Neuroscience, 2017
Neuromelanin (NM) is a dark pigment that accumulates linearly with aging in substantia nigra (SN) and locus coeruleus (LC). The dual protective and toxic role of NM has been hypothesized according to its intraneuronal or extraneuronal deposition. The melanized dopaminergic neurons in SN and LC seem to have special vulnerability to neurodegeneration in ...
Martin-bastida, Antonio, Pietracupa, Sara, Piccini, Paola   +2 more
openaire   +2 more sources

Botulinum toxin in the management of parkinsonian disorders

Toxicon, 2023
Many studies have shown that botulinum toxin (BoNT) can be an option to treat motor and non-motor symptoms in Parkinson's disease (PD) and parkinsonian syndromes. The advantages of BoNT compared to oral medications include localized action and low incidence of systemic side effects, which is important in treating neurodegenerative disease.
Talyta Grippe, Robert Chen
openaire   +2 more sources

Serial volumetric MRI in Parkinsonian disorders

Movement Disorders, 2009
AbstractTracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability.
Wild, E.J., Fox, N.C.I.
openaire   +4 more sources

Atypical Parkinsonian Disorders

Neurologic Clinics
Atypical parkinsonian disorders (APD) include progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy. Identifying APD is important because they have different pathogenesis, disease course, and prognosis than Parkinson's disease (PD), and require different treatments.
Nahid, Olfati, Fahimeh H, Akhoundi, Irene, Litvan   +2 more
openaire   +2 more sources

Update of atypical parkinsonian disorders

Current Opinion in Neurology, 2007
This timely update discusses novel diagnostic approaches, recently identified genes, and innovative experimental symptomatic treatments for these devastating disorders.Differential patterns in the basal ganglia transcranial sonography, magnetic resonance diffusion-weighted imaging regional apparent diffusion coefficients in the brainstem, basal ganglia
openaire   +2 more sources